Immunosuppression in patients with Crohn's disease and neoplasia: An ongoing clinical dilemma

Diseases of the Colon and Rectum

Volumn 55, Issue 9, 2012, Pages 1008-1011

  Dasari, Bobby V M ^a   McBrearty, Anthony ^a   Gardiner, Keith ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; PREDNISONE;

CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MALIGNANT TRANSFORMATION; MEDICAL LITERATURE; NEOPLASM; PATIENT SELECTION; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

6-MERCAPTOPURINE; AZATHIOPRINE; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS;

EID: 84866031720     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e31825d9269     Document Type: Review

References (20)

1. Lamers CB, Griffioen G, van Hogezand RA, Veenendaal RA. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol Suppl. 1999;230:111-115. (Pubitemid 29434519)
2. Prefontaine E, MacDonald JK, Sutherland LR. Azathiopurine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2010. CD000545.
3. Prefontaine E, Sutherland LR, MacDonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009. CD000067.
4. Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:119-130.
5. Beaugerie L, Brousse N, Bouvier AM, et al.; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617-1625.
6. Carter MJ, Lobo AJ, Travis SP. IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(suppl 5):V1-V16. (Pubitemid 39120096)
7. Maté-Jiménez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:1227-1233.
8. Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-483; quiz 464, 484.
9. D'Haens G, Baert F, van Assche G, et al. Belgian Inflammatory Bowel Disease Research Group. North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667. (Pubitemid 351284485)
10. Fotoohi AK, Coulthard SA, Albertioni F. Thiopurines: factors influencing toxicity and response. Biochem Pharmacol. 2010;79:1211-1220.
11. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther. 2001;15:1699-1708. (Pubitemid 33001133)
12. Overall evaluations of carcinogenicity. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans. Supp 7. Lyon, France: International Agency for Research on Cancer: 440.
13. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268-274.
14. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125. (Pubitemid 41025906)
15. van Asseldonk DP, Sanderson J, de Boer NK, et al. Thiopurine Task Force Interest Group. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease-proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis. 2011;43:270-276.
16. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656. (Pubitemid 43374514)
17. Bichari W, Bartiromo M, Mohey H, et al. Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases. Transplant Proc. 2009;41:672-673.
18. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK populationbased case-control study. Am J Gastroenterol. 2010;105:1604-1609.
19. Kälble T, Lucan M, Nicita G, Sells R, Burgos Revilla FJ, Wiesel M. European Association of Urology. EAU guidelines on renal transplantation. Eur Urol. 2005;47:156-166. (Pubitemid 40126971)
20. Woodle ES, Gupta M, Buell JF, et al. Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc. 2005;37:958-959. (Pubitemid 40590758)